Addus HomeCare Corp.

As of September 12, 2025, Addus HomeCare Corp. is in a bearish technical trend with mixed signals, underperforming the S&P 500 with a year-to-date return of -12.40% compared to the S&P's 12.22%.

As of August 4, 2025, Addus HomeCare Corp. is fairly valued with a P/E ratio of 23 and has underperformed the S&P 500, indicating it is neither undervalued nor overvalued compared to peers like The Ensign Group and U.S. Physical Therapy.

As of May 16, 2025, Addus HomeCare Corp. is considered very expensive with a P/E ratio of 23, an EV to EBITDA ratio of 16.07, and a PEG ratio of 1.38, while also underperforming against the S&P 500 with a year-to-date return of -9.84%.

As of March 2022, the management team of Addus HomeCare Corp. includes R. Dirk Allison (CEO), Steven Geringer (Chairman), and several independent directors: Michael Earley, Mark First, Darin Gordon, Veronica Hill-Milbourne, and Esteban Lopez. They oversee the company's operations and strategic direction.

Addus HomeCare Corporation provides personal care services primarily in-home and operates as a micro-cap company in the Pharmaceuticals & Biotechnology industry. As of March 2025, it reported net sales of $338 million and a net profit of $21 million, with a market cap of approximately $2.1 billion.

As of Jun 18, Addus HomeCare Corp. has a market capitalization of $2.1 billion, with net sales of $1.2 billion and a net profit of $79 million for the latest four quarters. The balance sheet as of December 2024 shows shareholder's funds of $970.5 million and total assets of $1.5 billion.